Faron Pharmaceuticals upbeat on latest data in blood cancer

Faron Pharmaceuticals announced encouraging updated data from its ongoing phase one and two ‘BEXMAB’ study into relapsed or refractory (r/r) acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) treatments on Wednesday.

Related Keywords

Markku Jalkanen , Faron Pharmaceuticals , Faron , Pharmaceuticals , Upbeat , Latest , Data , Blood , Cancer , Trials , Category All , Category Market Report , Category Company News , Category News And Announcements , Category Small Caps News , Category Aim Bulletin , Category Tecnologia , Category Market Pulse , Mostread Technology ,